| Policy challenges of nanomedicine for Australia's PBS. | |
| | |
MedLine Citation:
|
PMID: 19563314 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
All major pharmaceutical companies are currently investing significantly in the development of medicines with a nanotechnology component. Such research promises therapeutic drugs with greater efficacy and a wider range of clinical indications. Nanomedicines are just beginning to enter drug regulatory processes, but within a few decades could comprise a dominant group within the class of innovative pharmaceuticals. The current thinking of government safety and cost-effectiveness regulators appears to be that these products give rise to few if any nano-specific issues. This article challenges that proposition and seeks to explore what features of nanomedicines may create unique or heightened policy challenges for government systems of cost-effectiveness regulation. The Australian Pharmaceutical Benefits Scheme (PBS) is a key exemplar of the latter type of regulation in that it links expert scientific evaluation of cost-effectiveness with the pricing of PBS-listed drugs. In the current global financial crisis such systems are likely to become increasingly attractive and how they handle the demands made upon them by nanomedicines (including by application of a variation of the precautionary principle) is likely to be of considerable interest to policy makers worldwide. |
| | |
Authors:
|
Thomas A Faunce |
Related Documents
:
|
10101374 - Harm reduction: australia as a case study. 17867234 - Demand for illicit drugs among pregnant women. 12846924 - Spending on pharmaceuticals in italy: macro constraints with local autonomy. 15612334 - Reference pricing of pharmaceuticals for medicare: evidence from germany, the netherlan... 7157034 - Rational prescribing and sources of information. 16369884 - Bioavailability and pharmacokinetics of sulphadiazine, n4-acetylsulphadiazine and trime... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Australian health review : a publication of the Australian Hospital Association Volume: 33 ISSN: 0156-5788 ISO Abbreviation: Aust Health Rev Publication Date: 2009 May |
Date Detail:
|
Created Date: 2009-06-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8214381 Medline TA: Aust Health Rev Country: Australia |
Other Details:
|
Languages: eng Pagination: 258-67 Citation Subset: H |
Affiliation:
|
College of Law and School of Medicine, Australian National University, Acton, Canberra, ACT 0200. Thomas.Faunce@anu.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Biopharmaceutical innovation and industrial developments in South Korea, Singapore and Taiwan.
Next Document: Doctor and pharmacist - back to the apothecary!